Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Welcome to the TNL Beta! We are actively improving this experience.

Share Feedback

Source study found

Story checked

Scientists pinpoint hundreds of genetic variants that offer new insights into inherited breast cancer risk (opens in a new tab)

medicalxpress.com · 2026-11-05

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 2 supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Notice: Analysis is currently derived from study abstracts. Full-text paper analysis capabilities are currently in development.

Share this check

Help improve NewsLink

Tell us what worked or what needs attention in this check.

Follow the evidence trail
1

The story

Scientists pinpoint hundreds of genetic variants that offer new insights into inherited breast cancer risk

medicalxpress.com · 2026-11-05

The story’s checkable claims.

Read the original story (opens in a new tab)
2

NewsLink checks it

Mixed

Every claim we could check holds up. Two of four claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

  • 2 supported
  • 2 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4Not coveredScientists carried out one of the largest experimental studies of breast cancer variants to date, helping pinpoint genetic changes most likely to contribute to the disease.View evidenceHide evidence

As statedone of the largest experimental studies

Why this verdict

The abstract-level profile supports that the study used a large high-throughput lentiMPRA screen to prioritize breast-cancer GWAS credible causal variants, and that this helps prioritize candidate functional variants for downstream study. However, the comparative headline framing that it was 'one of the largest experimental studies ... to date' is not verifiable from the supplied abstract profile, which gives the scale but no comparison to other studies. The 'pinpoint' language is acceptable only insofar as it means prioritization rather than definitive causality.

1

Study evidence

A high-throughput lentiMPRA screen of 5,116 breast cancer credible causal variants identified 709 variants across 140 risk regions with significant allele-specific (REF vs ALT) regulatory activity.

“we carried out a lentivirus-based massively parallel reporter assay (lentiMPRA) to screen 5,116 credible causal variants (CCVs)”
2

Study evidence

A lentiMPRA screen of 5,116 credible causal variants was performed to identify allele-specific regulatory activity.

“These findings provide a prioritized set of functional variants for downstream analyses”
Claim 2 of 4Not coveredThe article says CCDC88C activity was higher in estrogen receptor-positive breast cancers than in estrogen receptor-negative tumors, and among ER-positive patients higher CCDC88C levels were associated with improved survival.View evidenceHide evidence

Why this verdict

The supplied abstract profile says the CCDC88C follow-up may have relevance to prognosis and ER-positive breast cancer, but it does not provide the specific claims that CCDC88C activity was higher in ER-positive than ER-negative tumors or that higher CCDC88C levels were associated with improved survival among ER-positive patients. Those directional clinical-expression and survival details may exist in the full paper, but they are not verifiable from the abstract-level evidence supplied.

1

Study evidence

At locus 14q32.11, follow-up work identifies rs7153397 as a variant that may influence breast cancer risk through modulation of CCDC88C expression; this regulatory link is proposed to have implications for prognosis and ER-positive disease.

“A follow-up investigation at 14q32.11 revealed that rs7153397 may influence breast cancer risk through expression of CCDC88C, which in turn could impact prognosis.”
Claim 3 of 4SupportedThe team analyzed over 5,000 genetic variants linked to breast cancer risk and identified over 700 across 140 risk regions that appeared to alter gene activity.View evidenceHide evidence

As statedover 5,000; over 700; 140 risk regions

Why this verdict

The paper profile states that the authors screened 5,116 credible causal variants and identified 709 variants mapping to 140 risk regions with significant REF-versus-ALT regulatory activity. The story's 'over 5,000,' 'over 700,' and '140 risk regions' wording accurately reflects those abstract-level results, and its hedged 'appeared to alter gene activity' framing is consistent with allele-specific reporter regulatory activity.

1

Study evidence

A high-throughput lentiMPRA screen of 5,116 breast cancer credible causal variants identified 709 variants across 140 risk regions with significant allele-specific (REF vs ALT) regulatory activity.

“we carried out a lentivirus-based massively parallel reporter assay (lentiMPRA) to screen 5,116 credible causal variants (CCVs)”
2

Study evidence

A lentiMPRA screen of 5,116 credible causal variants was performed to identify allele-specific regulatory activity.

“These findings provide a prioritized set of functional variants for downstream analyses”
Claim 4 of 4SupportedLaboratory follow-up suggested CCDC88C is a likely target of the risk variant rs7153397, and the variant appeared to affect regulation of that gene.View evidenceHide evidence

Why this verdict

The abstract-level profile reports a locus-specific follow-up at 14q32.11 in which rs7153397 was nominated as potentially influencing breast cancer risk through CCDC88C expression. The story's wording is hedged—'suggested,' 'likely target,' and 'appeared to affect regulation'—so it does not claim definitive proof. Exact follow-up methods are not available at abstract depth, but the core rs7153397–CCDC88C regulatory interpretation is supported.

1

Study evidence

At locus 14q32.11, follow-up work identifies rs7153397 as a variant that may influence breast cancer risk through modulation of CCDC88C expression; this regulatory link is proposed to have implications for prognosis and ER-positive disease.

“A follow-up investigation at 14q32.11 revealed that rs7153397 may influence breast cancer risk through expression of CCDC88C, which in turn could impact prognosis.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Important limitation: MPRA findings are generated in an in vitro reporter-assay context and may not fully capture endogenous chromatin context, cell-type specificity, or in vivo regulatory consequences.

    The story mentions that the work does not by itself identify causal variants and gene targets, but the supplied caveats do not explicitly acknowledge the in vitro reporter-assay limitation or its implications for endogenous and in vivo relevance.

    From lentiMPRA high-throughput screen of CCVs; lentiMPRA-derived cataloging / curation

  • Important limitation: the abstract provides no effect estimates, statistical metrics, data sources, or detailed methods for the rs7153397–CCDC88C follow-up and prognosis/ER-positive disease associations.

    The story uses hedged language for the follow-up, but the supplied caveats do not specifically communicate that the abstract-level evidence lacks methodological and quantitative detail for the CCDC88C/prognosis claims.

    From locus-specific follow-up

5 things the story did carry across
  • The paper's central experiment was a lentivirus-based massively parallel reporter assay screening 5,116 breast cancer credible causal variants across 196 GWAS risk signals for allele-specific cis-regulatory activity.
  • The main quantitative result was identification of 709 variants across 140 risk regions with significant REF-versus-ALT regulatory activity in the lentiMPRA assay.
  • The paper frames the output as a prioritized catalog/resource of functional, allele-specific regulatory variants for downstream mechanistic analyses, not as definitive proof of causal disease variants.
  • A locus-specific follow-up at 14q32.11 nominated rs7153397 as potentially regulating CCDC88C expression, with possible relevance to breast cancer prognosis and ER-positive disease.
  • Important limitation: linkage disequilibrium and GWAS fine-mapping uncertainty mean MPRA signals prioritize candidate variants but do not by themselves establish single-variant causality at a locus.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

in vitro

1Lead resultin vitroSystematically prioritize breast cancer GWAS credible causal variants (CCVs) by testing allele-specific cis-regulatory activity using a lentivirus-based massively parallel reporter assay (lentiMPRA) across many loci.lentiMPRA high-throughput screen of CCVsExpand

In plain English

The authors performed a lentivirus-based massively parallel reporter assay (lentiMPRA) to functionally screen 5,116 credible causal variants (CCVs) from 196 breast cancer GWAS risk signals for allele-specific cis-regulatory activity. The screen identified 709 variants across 140 risk regions with significant differences between reference (REF) and alternative (ALT) alleles. A locus-specific follow-up at 14q32.11 highlighted rs7153397 as a candidate regulator of CCDC88C expression with potential implications for prognosis. The dataset provides a prioritized set of regulatory candidate variants for downstream functional and mechanistic studies.

Key findings

  • A high-throughput lentiMPRA screen of 5,116 breast cancer credible causal variants identified 709 variants across 140 risk regions with significant allele-specific (REF vs ALT) regulatory activity.
  • Locus-specific follow-up at 14q32.11 nominated rs7153397 as a variant that may influence breast cancer risk through effects on CCDC88C expression, with potential implications for prognosis.
“we carried out a lentivirus-based massively parallel reporter assay (lentiMPRA) to screen 5,116 credible causal variants (CCVs)”
What this piece can’t prove
  • Functional prioritization is based on an in vitro lentiviral MPRA and may not fully capture endogenous chromatin context, cell-type specificity, or in vivo regulatory consequences.
  • Linkage disequilibrium among GWAS variants complicates attribution of causal effects to single variants; MPRA signals prioritize candidates but do not by themselves establish causality at the locus.

1 further detail could not be confirmed from the summary.

2otherPerform locus-specific follow-up at 14q32.11 to implicate rs7153397 in regulation of CCDC88C and suggest relevance to ER-positive breast cancer risk/prognosis.locus-specific follow-upExpand

In plain English

Locus-specific follow-up at 14q32.11 linked the MPRA-prioritized variant rs7153397 to allele-specific regulation of CCDC88C expression and posits that this regulatory effect could mediate breast cancer risk and influence prognosis, with relevance suggested for ER-positive disease. Specific experimental or analytical methods and effect sizes are not reported in the abstract.

Key findings

  • At locus 14q32.11, follow-up work identifies rs7153397 as a variant that may influence breast cancer risk through modulation of CCDC88C expression; this regulatory link is proposed to have implications for prognosis and ER-positive disease.
“A follow-up investigation at 14q32.11 revealed that rs7153397 may influence breast cancer risk through expression of CCDC88C, which in turn could impact prognosis.”
What this piece can’t prove
  • No effect estimates, statistical significance values, or data sources for the follow-up associations are reported.

2 further details could not be confirmed from the summary.

3otherProvide a community resource: a prioritized catalog of functional, allele-specific regulatory variants across breast cancer risk regions for downstream mechanistic studies.lentiMPRA-derived cataloging / curationExpand

In plain English

The paper delivers a prioritized catalog/resource of allele-specific, regulatory breast cancer risk variants derived from a lentivirus-based massively parallel reporter assay (lentiMPRA). From screening 5,116 credible causal variants, the authors report 709 variants across 140 risk regions with significant REF-versus-ALT regulatory differences and present these as a prioritized set intended for downstream mechanistic and analytic use.

Key findings

  • A lentiMPRA screen of 5,116 credible causal variants was performed to identify allele-specific regulatory activity.
  • 709 variants across 140 breast cancer risk regions showed significant REF-versus-ALT regulatory differences in the lentiMPRA.
“These findings provide a prioritized set of functional variants for downstream analyses”
What this piece can’t prove
  • The abstract does not provide per-variant effect sizes, statistical thresholds, nor explicit data-access details for the prioritized catalog.
  • The prioritized set is derived from the tested panel of 5,116 credible causal variants and therefore excludes variants not included in that screen.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 37 candidate papers

And 31 more candidates considered.